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a b s t r a c t
In 2009 a new inﬂuenza A/H1N1 virus strain (“pandemic (H1N1) 2009”, H1N1v) emerged that rapidly
spread around the world. The virus is suspected to have originated in swine through reassortment and
to have subsequently crossed the species-barrier towards humans. Several cases of reintroduction into
pigs have since been reported, which could possibly create a reservoir for human exposure or ultimately
become endemic in the pig population with similar clinical disease problems as current swine inﬂuenza
strains. A soluble trimer of hemagglutinin (HA), derived from the H1N1v, was used as a vaccine in pigs
to investigate the extent to which this vaccine would be able to protect pigs against infection with
the H1N1v inﬂuenza strain, especially with respect to reducing virus replication and excretion. In a
group of unvaccinated control pigs, no clinical symptomswere observed, but (histo)pathological changesemagglutinin
oluble trimer
wine
andemic
consistentwith an inﬂuenza infectionwere foundondays1 and3after inoculation. Live viruswas isolated
from the upper and lower respiratory tract, with titres up to 106 TCID50 per gram of tissue. Furthermore,
live virus was detected in brain samples. Control pigs were shedding live virus for up to 6 days after
infection, with titres of up to 105 TCID50 per nasal or oropharyngeal swab. The soluble H1N1v HA trimer
diminished virus replication and excretion after a double vaccination and subsequent challenge. Live
virus could not be detected in any of the samples taken from the vaccinated pigs. Vaccines based on
e ansoluble HA trimers provid
. Introduction
In April 2009 a new inﬂuenza A/H1N1 virus strain was detected
n two children in Southern California, both suffering from res-
iratory disease [1]. Full sequence analysis showed that this
ew inﬂuenza strain, currently named “pandemic (H1N1) 2009”
H1N1v), is likely a reassortant between North American and
urasian swine inﬂuenza strains [2,3]. Unlike most other introduc-
ions of swine inﬂuenza strains in the humanpopulation, this strain
as successful in human-to-human transmission. The virus spread
uickly to other countries and continents and ﬁnally, on the 11th
une 2009, the WHO declared this outbreak to be a pandemic, the
rst one since 1968 (Hong Kong ﬂu).
On 28 April 2009, the Canadian Food Inspection Agency became
nvolved in the ﬁrst ﬁeld infection of swine with this H1N1v [4].
ntroductionof thevirus throughan infectedhumanwas suspected,
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but could not be proven. On the 25th June, a second swine herd,
in Argentina, was reported to the World Organization for Animal
Health (OIE) as being infected [5]. Also in this case, introduction
through infected humans was suspected, but could not be con-
ﬁrmed. In both cases the clinical symptoms in the pigs were rather
mild and recovery of the pigs was uneventful. Many more such
cases in swine herds have since been detected, in countries all over
the world.
The susceptibility of pigs to this particular virus strain has been
conﬁrmed in several experimental studies [6–8]. Clinical symptoms
in pigs were shown to be similar to those caused by endemic swine
inﬂuenza strains. It was also shown that virus transmission to sus-
ceptible pigs, at least those naïve for antibodies against any swine
inﬂuenza viruses, readily occurs.Whether theH1N1v is able to out-
compete endemic H1N1 and/or H1N2 strains, or whether it would
be able to co-exist with these endemic strains in swine, is as yet
unknown. In such cases pigs may become a reservoir from which
Open access under the Elsevier OA license.repeated introductions into the human population could occur.
It can be expected that the more widespread the infection
becomes in humans, the more often the virus will be introduced in
swine. Infected pigs may therefore become a source of infection for
humans, even if the virus would not succeed in becoming endemic
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n the pig population. Humans in contact with high concentrations
f infected pigs may be exposed to much higher amounts of virus
han when exposed to infected humans. This could result in much
ore severe clinical symptoms, even in a higher mortality. Possi-
le contact persons are not just the farmers and their family, but
lso include veterinarians, pig consultants, traders, transporters,
isitors of pig markets and slaughterhouse personnel.
A way to decrease the risk for people involved may be vacci-
ation of pigs, with the primary aim of reducing virus excretion
nd therefore exposure of humans to the virus. Conventional vac-
ines consist of whole viruses propagated in either embryonated
hicken eggs or cell cultures, which are subsequently inactivated
nd adjuvanted. In case new such vaccines, based on new inﬂuenza
ubtypes, are needed, the development, registration and subse-
uent production takes a relatively long time, taking care of safety,
fﬁcacy and production issues. As an alternative a recombinant
uriﬁed hemagglutinin (HA) could be used as a vaccine. One such
ecombinant, a secretable, soluble trimer of the HA ectodomain
rom the H1N1v inﬂuenza strain, was constructed and formulated
s a vaccine to be tested in swine. The aim of this study was to
etermine to what extent this vaccine is able to protect against
nfection with the H1N1v inﬂuenza strain, especially with respect
o reducing virus replication and excretion. It was shown that the
A trimer was almost complete able to prevent virus replication
nd excretion after a double vaccination.
. Materials and methods
.1. Study design
The study was carried out with 18 pigs, divided into two groups
f 9. In one group the pigs were vaccinated twice, with a four week
nterval. At the age of 10 weeks they were vaccinated for the ﬁrst
ime. The other group was an unvaccinated control group. Three
eeks after the secondvaccination the animals in both groupswere
hallenged, resp. inoculated with the H1N1v virus. At days 1 and 3
ost inoculation (p.i.) 3 pigs from each group were euthanized. The
emaining 3 pigs in each group were euthanized at day 21 p.i., the
nd of the experiment.
The design of the experiment was evaluated and approved by
he Ethical Committee for Animal Experiments of the Animal Sci-
nces Group.
.2. Animals
Nine-week-old piglets were purchased from a high-health
reeding herd in which no seroconversions against any inﬂuenza
ubtype had been observed for more than 2 years. Before purchas-
ng the pigs, all were tested individually with an NP-ELISA (IDEXX)
nd in hemagglutination inhibition assays against H1N1, H1N2 and
3N2 inﬂuenza virus strains that are endemic in the swine popu-
ation.
.3. Vaccine and vaccination
BasedonH3numbering, a cDNAclonecorresponding to residues
6–524 of the HA from A/California/04/2009(H1N1) (Genbank
ccession no. ABW90137.1) was synthesized using human-
referred codons by GenScript USA Inc. The HA ectodomain-
ncoding cDNA was cloned into the pCD5 expression vector
or efﬁcient expression in mammalian cells [9]. The pCD5-
al/04/09 vector had been modiﬁed such that the HA-encoding
DNA was cloned in frame with DNA sequences coding for a
ignal sequence, a GCN4 isoleucine zipper trimerization motif
KRMKQIEDKIEEIESKQKKIENEIARIKK) [10] and the Strep-tagII
WSHPQFEK; IBA, Germany). The HA ectodomain was expressed29 (2011) 1545–1550
in HEK293T as previously described [11]. HA protein expression
and secretion was conﬁrmed by sodium dodecylsulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) followed by western
blotting using a mouse anti-Strep-tag antibody (IBA, Germany).
Secreted HA proteins were puriﬁed using Strep-tactin sepharose
beads according to themanufacturer’s instructions (IBA, Germany).
The concentration of puriﬁed protein was determined by using a
Nanodrop 1000 spectrophotometer (Isogen Life Sciences) accord-
ing the manufacturer’s instructions. Oligomeric status of the
HA protein was determined by analyzing the elution proﬁle
using a Superdex200GL 10–300 column and by blue-native gel-
electrophoresis. The vaccine was formulated with Specol [12,13]
as an adjuvant, at 25g HA per dose of 2ml. Pigs were vaccinated
intramuscularly.
2.4. Virus and inoculation
Inﬂuenza virus A/Netherlands/602/2009 (H1N1)v was isolated
from the ﬁrst conﬁrmed case in the Netherlands [14]. The patient
was a 3-year old boy, developing a fever and symptoms of respi-
ratory disease after returning from Mexico with his family. A nasal
swab was taken before the patient was treated with oseltamivir.
Virus was initially grown on embryonated eggs, and subsequently
passagedonMadin–Darby caninekidney (MDCK) cells before itwas
used to inoculate the pigs. This virus differs by 8 amino acids from
the A/California/4/2009 (H1N1)v strain [14]. Because it is, however,
closer to the consensus sequence, it is considered representative of
the circulating H1N1v inﬂuenza strains.
Pigs were inoculated with a dose of 107.5 TCID50, suspended in
2ml PBS, of which 1ml was nebulised within each nostril.
2.5. Observations and sampling
Clinical symptoms and body temperature were recorded daily
from day 3 before inoculation until the end of the experiment.
At days 1–3 p.i. clinical symptoms and body-temperature were
recorded twice per day with a 12h interval.
Serum sampleswere collected during both times of vaccination,
at the time of inoculation, and 7, 10, 14 and 21 days p.i.
Oropharyngeal and nasal swabs were collected daily from all
animals still alive from day 0 to 11 p.i., and on days 14, 17 and
21 p.i. For oropharyngeal swabs multi-layered gauze dressings in
a pair of tweezers were used to scrape the palatine tonsils at the
dorsal pharyngeal wall, behind the soft palate. Nasal swabs were
collected using sterile rayon swabs (Medical Wire & Equipment,
Corsham, United Kingdom). The swabs were suspended in 4ml
(oropharyngeal swabs) or 2ml (nasal swabs) medium (Eagle min-
imum essential medium (EMEM) (Gibco, Invitrogen, Breda, The
Netherlands)with5% fetal bovine serum(FBS), and10%antibiotics).
After centrifugation (1800× g for 15min) the samples were stored
at −70 ◦C until analysis.
At days 1 and3p.i. 3 pigs fromeachgroupwere euthanized anda
gross pathological examination was performed. Thirteen different
tissue samples were collected from each of these pigs for histo-
logical and/or virological examinations: nasal mucosa from the
turbinates, tonsils, trachea, tracheobronchial lymph nodes (TBLN),
six pieces of lung, brainstem, cerebrum and cerebellum. The lung
pieces originated from the right apical lobe (lung 1), the right car-
diac lobe (lung 2), the right diaphragmatic lobe (lung 3), the left
diaphragmatic lobe (lung 4), the left cardiac lobe (lung 5), and the
left apical lobe (lung 6).For (immuno)histology, tissue sampleswereﬁxed in10%neutral
buffered formalin for a maximum of 48h, embedded in paraf-
ﬁn and tissue slides were stained with hematoxylin and eosin.
For immunohistological evaluation tissue slides were mounted
on silicon coated glass slides, deparafﬁnised and exposed to 1%
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2O2 to block endogenous peroxidase. After washing, the slides
ere treated with protease type XXIV (0.1mg/ml, diluted in PBS,
igma®, order nr. P8038) for 10min. Samples were incubated with
0% normal goat serum and thereafter incubated with a murine
onoclonal antibody, directedagainst the InﬂuenzaAvirusnucleo-
rotein (HB65MCA) for 45min. After rinsing, slideswere incubated
ith a HRP labelled polymer conjugated to an anti-murine IgG
ntibody (DAKOEnvisionTM+System)and tovisualize the immuno-
istochemical signal followedby treatmentwithdiaminobenzidine
etrahydrochloride and counterstaining with hematoxylin eosin.
For virological examination, 0.1 g from each tissue sample was
dded to 0.6ml of medium (same as used for the swabs), and
omogenized using the MagNaLyser (Roche Applied Science) for
0 s at 3500× g. After centrifugation (9500× g for 5min), 0.4ml of
he supernatantwasadded toa further1.2mlofmediumandstored
t −70 ◦C until analysis.
At day 21 p.i. the remaining pigs where euthanized. Lungs were
ollected for a broncho-alveolar lavage, using 50ml of cold (4 ◦C)
hosphate-buffered saline (PBS). The broncho-alveolar lavage ﬂuid
BALF) obtained was centrifuged (9500× g for 5min) and stored at
70 ◦C until analysis.
.6. PCR
Nasal swabs, oropharyngeal swabs, tissue homogenates and
ALF were all tested with a quantitative real time RT-PCR
qRT-PCR). A one-tube qRT-PCR was performed to detect the
atrix gene of the inﬂuenza virus. The Qiagen one-step
T-PCR kit was used with a 25l reaction mixture con-
aining 1l of kit-supplied enzyme mixture, 1l dNTP mix,
U of RNase inhibitor (Promega, Madison, WI), 0.5M of
ach primer M-Fw (5′-CTTCTAACCGAGGTCGAAACGTA-3′), M-Rev
5′-CACTGGGCACGGTGAGC-3′), and 0.3M of probe M (5′-6FAM-
CAGGCCCCCTCAAAGCCGA-X-ph). The qRT-PCR was performed
ith the MX4000 (Stratagene®, Texas). The RT-PCR program con-
isted of 30min at 50 ◦C and 15min at 95 ◦C. A three-step cycling
rotocol was used as follows: 95 ◦C for 5 s, 58 ◦C for 15 s, and of
2 ◦C for 20 s for 45 cycles. In each PCR run a standard curve was
ncluded with a known virus concentration. Results of the PCR are
xpressed as TCID50-equivalents per swab or per gram of tissue.
CID50-equivalents are a relative measure and not necessarily rep-
esent live virus.
.7. Virus isolation
Nasal swabs, oropharyngeal swabs, tissue homogenates and
ALF were all tested in a virus isolation with end-titration on
DCK-I-BD5 cells [15]. Samples were initially diluted with the
ame amount of GMEM/EMEM medium containing 1% bovine
erum albumin and antibiotics (twofold dilution). This initial
ilution was serially diluted tenfold in the same medium. The
iluted samples (100l/well) were mixed with 150l of 2×105
DCK-I-BD5 cells/ml and incubated for 48h at 37 ◦C and 5% CO2.
he monolayers were subsequently washed with PBS, frozen at
20 ◦C and ﬁxed with 4% cold (4 ◦C) paraformaldehyde for 10min.
fter washing, viral NP-protein-containing cells were stained
sing HRPO-conjugated monoclonal antibody HB65 and 3-amino-
-ethyl-carbozole (AEC; Sigma–Aldrich, The Netherlands) as a
ubstrate for HRPO. Samples were tested in eightfold and titres
ere calculated according to the method of Spearman-Kärber [16].
irus titres are expressed as TCID50 per swab or per gram of tissue..8. Hemagglutination inhibition test
The hemagglutination inhibition (HI) test was carried out as
escribed before [17]. Before testing, samples were inactivated for29 (2011) 1545–1550 1547
30min at 56 ◦C. Subsequently they were pre-treated with receptor
destroying enzyme (RDE) and chicken red blood cells to remove
non-speciﬁc agglutinins and hemagglutination inhibitors. Start-
ing at an initial dilution of 1:10, sample were tested in two-fold
dilution series. Samples were incubated for 60min after adding
antigen and another 45min after adding chicken red blood cells
and subsequently read. The antigens used in the test were the
A/Netherlands/602/2009 (H1N1)v and, for swine inﬂuenza, the
A/Swine/Best/96 (H1N1) [18] and A/Swine/Gent/7625/99 (H1N2)
[19]. All were standardised at 4 hemagglutinating units per 25l.
2.9. Virus neutralisation test
The virus neutralisation tests were performed on MDCK-I-BD5
cells [15]. Serawere heat inactivated for 30min at 56 ◦C before test-
ing. Twofold serial dilutions of the seraweremade inGMEM/EMEM
medium containing 1% bovine serum albumin and antibiotics in
96-well plates. The diluted sera (50l/well) were mixed with 100
TCID50 of the inﬂuenza viruses (50l) and incubated at 37 ◦C and
5% CO2 for 1h. Thereafter 150l of 2×105 MDCK-I-BD5 cells/ml
were added to each well. The plates were incubated at 37 ◦C
and 5% CO2 for 48h. The monolayers were washed with PBS,
frozen at −20 ◦C and ﬁxed with 4% cold (4 ◦C) paraformaldehyde
for 10min. After washing, viral NP-protein-containing cells were
stained using HRPO-conjugated monoclonal antibody HB65 and 3-
amino-9-ethyl-carbozole (AEC; Sigma–Aldrich, The Netherlands)
as a substrate for HRPO. A complete lack of staining was scored as
positive neutralisation. VN-antibody titres were expressed as the
reciprocal of the highest serum dilution giving positive neutralisa-
tion.
3. Results
3.1. Clinical symptoms
No clinical symptoms were observed in any of the inoculated
animals, neither in the control group, nor in the vaccinated group.
Body temperatures of all animals remained within normal range
during the whole animal experiment. One of the pigs from the
vaccinated group died between the ﬁrst and second vaccination
of unrelated causes (Mulberry heart disease) and could not be
replaced. In this group therefore only 2 pigs were left after day
3 p.i. until the end of the experiment at day 21 p.i.
3.2. Pathological and histological ﬁndings
At day 1 p.i. some reduced retraction of the lungs was observed
in one of the control pigs, and some moderate hyperaemia of the
nasal mucosa in one of the vaccinated pigs. Histology of the lungs
revealed a slight to mild focal interstitial pneumonia in all con-
trol pigs, accompanied with a mild catarrhal bronchiolitis in one
of them. A slight focal interstitial pneumonia was present in one
of the vaccinated pigs. Immunohistochemistry showed the pres-
ence of virus in lungs and nasal mucosa of all control pigs, and
in some individual cases also in the trachea, tonsil and tracheo-
bronchial lymph node. Vaccinated pigs were all negative in the
immunohistochemistry.
Gross pathology revealed at 3 days p.i. a mild to moderate focal
ormultifocal pneumonia in all control pigs. In twoof the vaccinated
pigs amild reduced retractionof the lungswasobserved,with some
moderatehyperaemiaof the trachea in oneof these cases, and some
moderate hyperaemia of the nasal mucosa in the other. Histology
revealed amild tomoderate interstitial pneumonia in all three con-
trol pigs, with a moderate catarrhal bronchitis/bronchiolitis with
focal epithelial necrosis and intra luminal cell debris in two of these
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ig. 1. Average virus isolation (VI; in log TCID50) and PCR (in log TCID50 equivalents
accinated group respectively, n=6/5 on days 2 and 3 p.i. and n=3/2 on days 4–21
igs. Two of the three vaccinated pigs showed some slight inter-
titial pneumonia. Immunohistochemistry of the lungs was again
ositive in all three control pigs, with 2 of them also positive in the
asal mucosa and trachea. Vaccinated pigs were all negative in the
mmunohistochemistry.
.3. Antigen detectionFromall control pigs, live virus could already be isolated at day 1
.i. fromnasal andoropharyngeal swabs, at titres ranging from102.4
o 106.4 TCID50 per swab. Comparable virus titres were observed
ntil day 4 p.i., declining thereafter. No live virus could be isolated
ig. 2. Average virus isolation (VI; in log TCID50) and PCR (in log TCID50 equivalents) titre
re shown.dpi
s in nasal and oropharyngeal swabs (n=9/8 on days 0 and 1 p.i. for the control and
andard deviations are shown.
from day 6 p.i. (nasal swabs) or day 7 p.i. (oropharyngeal swabs)
onward, respectively. Virus titres seemed overall slightly higher in
oropharyngeal swabs than in nasal swabs. From none of the vacci-
nated pigs live virus could be isolated from nasal or oropharyngeal
swabs at any time (Fig. 1A and B).
Viral genome titres peaked on the same days as live virus, but
could be detected somewhat longer, until day 10 p.i. in oropha-
ryngeal swabs and day 9 p.i. in nasal swabs from control animals
(although one further single weak positive nasal swab was found
on day 14 p.i.). From the vaccinated pigs, only on day 1 p.i. genome
was detected from multiple animals, but at low amounts (Fig. 1C
and D).
s in 13 different pieces of tissue (3 pigs per day and per group). Standard deviations
W.L.A. Loeffen et al. / Vaccine 29 (2011) 1545–1550 1549
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Fig. 4. Average hemagglutination inhibition (HI) titres when using H1N1 and H1N2
itres against H1N1v after vaccination and subsequent challenge (n=9/8 before and
n the day of challenge for the control and vaccinated group respectively, n=3/2
fter the challenge). Standard deviations are shown.
Onday 1p.i. live virus could be isolated from the control animals
romtheupperand lower respiratory tract,with thehighest titres in
he nasal mucosa and trachea. Low amounts of live virus were also
etected in the cerebrumand cerebellum.No live viruswas isolated
rom TBLN (Fig. 2A). On day 3 p.i. live virus was only detected from
he upper and lower respiratory tract, but no longer from parts of
he central nervous system and still not from the TBLN (Fig. 2B).
rom the vaccinated animals no live virus could be isolated from
ny of the tissue samples at either time point. (Fig. 2A and B)
On days 1 and 3 p.i. virus genome could be detected by PCR from
ll tissue samples from the control pigs, including from the TBLN
nd central nervous system. In only one of the vaccinated animals,
iral genome was detected in nasal mucosa at day 1 p.i. (Fig. 2C and
).
BALF frompigs euthanized at day 21p.i. was negative in the PCR.
.4. Serology
Already after the ﬁrst vaccination, at the time of the second vac-
ination, high antibody titres against the homologousH1N1v strain
ere seen, both in the HI-test (Fig. 3A) and in a VNT (Fig. 3B). The
econd vaccination resulted in a further rise of these antibody titres
o levels >10,000.
After inoculation with the challenge virus, the non-vaccinated
nimals responded with titres up to 2560, peaking at 10 days p.i.
nd then decreasing again. In the vaccinated animals almost no
hanges were seen in the levels of the titres after the challenge
Fig. 3A and B).
Cross-reactivity, both after vaccination and after inocula-
ion/challenge, was seen in HI-tests and VNT when a swine
nﬂuenza strain of subtypeH1N1was used in the test, but notwhen
n H1N2 strain of swine origin was used. Results for the HI-tests
re shown in Fig. 4. VNT results are not shown as they were almost
dentical to the HI-results.subtypes of swine origin after vaccination and challenge (n=9/8 before and on the
day of challenge for the control and vaccinated group respectively, n=3/2 after the
challenge). Standard deviations are shown.
4. Discussion
ThesolubleH1N1vHAtrimerwasalmost completelyable topre-
vent virus replication and excretion after a double vaccination and
subsequent homologues challenge. Live virus could not be detected
in any of the samples taken from the vaccinated pigs. Viral genome
was only detected at day 1 p.i. in nasal and oropharyngeal swabs
and at day 1 p.i. in the nasal mucosa from one of the euthanized
pigs. The amount of genome detected from the swabs was very
low, but genome could be detected in multiple animals. This viral
genome may very well represent residual challenge virus. How-
ever, some very limited virus replication in the upper respiratory
tract in the vaccinated groups can not be excluded, as high levels of
virus replication were already observed at day 1 p.i. in the control
group.
A recombinant puriﬁed HA has several advantages compared to
whole inactivated vaccines. Most importantly, the development of
a HA-based vaccine has a relatively short lead-time, allowing for a
fast response to a potential emergency situation. It can be produced
using safe and scalable conditions, without the need of growing
live viruses and the disadvantages related to that. HA vaccines also
allow for the use as marker vaccines, although this will depend
also on other circulating inﬂuenza strains in the target population.
Marker vaccines make it possible to serologically detect and moni-
tor infections in a vaccinated population, allowing for the collection
of invaluable epidemiological data.
The advantage of recombinant HA trimers over recombinant HA
monomers is that the former induce higher levels of neutralising
antibodies [20]. In part this is likely due to the fact that trimers
mimic the natural membrane-bound structure, including the rele-
vant epitopes to induce neutralising antibodies against. Trimeric
HA preparations therefore seem more promising vaccine candi-
dates than previously used HA monomers.
Vaccination of pigs reduces the exposure of humans to the
inﬂuenza virus almost completely. In case pigs are deemed a poten-
1 accine
t
e
T
S
m
b
o
d
t
o
d
w
r
f
a
i
u
o
a
p
c
m
t
v
o
c
i
m
d
o
d
i
s
s
m
l
i
r
i
e
d
s
o
E
H
t
p
A
a
V
i
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
reassortment between avian and human inﬂuenza A viruses in Italian pigs.
Virology 1993;193(1):503–6.550 W.L.A. Loeffen et al. / V
ial source of infection for humans, vaccination of herds at risk, or
ven the entire pig population, therefore seems a realistic option.
he vaccine could however also be used for humans themselves.
imilar results with an HA trimer based on H5N1 in poultry and
ice [21], but also ferrets [22], suggest that the use of these recom-
inant HA trimers is promising in general.
In this experiment we used a rather high dose of HA as proof
f principle for the soluble trimer. Further studies would need to
etermine the efﬁcacy of the vaccine at lower doses. The lower
he dose, the easier it would be to produce sufﬁcient quantities
f vaccine in a short time, which is one of the most crucial issues
uring a pandemic or other emergency situation. Furthermore, it
ould make the vaccine more cost-affordable, which is especially
elevant for continuous use of the vaccine in pig herds, for instance
or use of this kind of vaccines against swine inﬂuenza strains that
re endemic.
Contrary to previous inoculation studies with the H1N1v
nﬂuenza virus [6–8], no clinical symptoms were seen in the inoc-
lated control animals. Nevertheless, virus titres from nasal and
ropharyngeal swabs were higher than published before [7], and
lso relatively high virus titres were found in all parts of the lungs,
roviding sufﬁcient evidence that the inoculation itself was suc-
essful. Furthermore, pathological changes, both macroscopic and
icroscopic, were abundantly present in the unvaccinated con-
rols, while only some minor changes were seen in some of the
accinated pigs. In our study the pigs were much older than in the
ther published studies. Whether this explains the lack of clini-
al symptoms, remains to be seen. In a previous study with swine
nﬂuenza virus in naïve pigs, clinical symptoms seemed to be even
ore severe in older pigs [23].
Antibodies against the H1N1v inﬂuenza virus are readily
etected by an HI assay in which a current European swine strain
f the H1N1 subtype is used. This cross-reactivity may result in
ifﬁculties to correctly identify infections in swine with H1N1v
nﬂuenza strains by serology. Infectionswith swineH1N1 inﬂuenza
trains are very common in many European countries, with
eroprevalences in sows up to 80%, and herd prevalences up to
ore than 95% [24]. On the other hand, due to this high preva-
ence of H1N1 antibodies, it may be more difﬁcult for the H1N1v
nﬂuenza virus to become endemic in the swine population. Cur-
ently no reports can be found that suggest a wide spread of H1N1v
nﬂuenza virus in swine populations where other H1N1 strains are
ndemic. It remains to be seenhow the epidemiology ofH1N1vwill
evelop, whether it will be able to co-circulate with current H1N1
trains or whether one strains will eventually predominating the
ther. Furthermore, recombination with current swine strains in
urope could occur, as happened before with the European swine
3N2 [25] and H1N2 strain [26]. This could increase the poten-
ial of the H1N1v inﬂuenza strain to become endemic in the swine
opulation.
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